相似文献
1
Integrative genomic profiling of human prostate cancer.
Cancer Cell. 2010 Jul 13;18(1):11-22. doi: 10.1016/j.ccr.2010.05.026. Epub 2010 Jun 24.
2
Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
J Pathol. 2013 Sep;231(1):130-41. doi: 10.1002/path.4223.
3
Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer.
Cancer Res. 2009 Oct 1;69(19):7793-802. doi: 10.1158/0008-5472.CAN-08-3810. Epub 2009 Sep 22.
4
TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Cancer Res. 2006 Nov 15;66(22):10658-63. doi: 10.1158/0008-5472.CAN-06-1871.
5
Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
Mol Carcinog. 2015 Sep;54(9):900-7. doi: 10.1002/mc.22162. Epub 2014 Apr 29.
6
7
Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience.
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2020 Jun 1;41(1):5-14. doi: 10.2478/prilozi-2020-0018.
8
Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.
Cancer Res. 2009 Jan 15;69(2):640-6. doi: 10.1158/0008-5472.CAN-08-2008.
9
TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
Cancer Lett. 2018 Dec 1;438:32-43. doi: 10.1016/j.canlet.2018.08.027. Epub 2018 Sep 7.
10
Characterize the difference between TMPRSS2-ERG and non-TMPRSS2-ERG fusion patients by clinical and biological characteristics in prostate cancer.
Gene. 2018 Dec 30;679:186-194. doi: 10.1016/j.gene.2018.09.006. Epub 2018 Sep 6.
引用本文的文献
1
A Brief Review of MicroRNA Profiling in Human Prostate Cancer Tissues and Plasma.
Biomolecules. 2025 Aug 12;15(8):1156. doi: 10.3390/biom15081156.
2
PTEN restoration and CXCR2 depletion synergistically enhance the effect of enzalutamide and inhibit bone metastatic CRPC.
Theranostics. 2025 Jul 25;15(16):8488-8508. doi: 10.7150/thno.114534. eCollection 2025.
3
ERG-driven prostate cancer initiation is cell-context dependent and requires KMT2A and DOT1L.
Nat Genet. 2025 Aug 26. doi: 10.1038/s41588-025-02289-w.
4
Single-Cell and Bulk RNA Sequencing Highlights Intra-Tumoral Heterogeneity and Malignant Progression Mechanisms in Prostate Cancer.
J Cell Mol Med. 2025 Aug;29(16):e70806. doi: 10.1111/jcmm.70806.
5
The prognostic value of PTEN expression in localized prostate cancer.
World J Urol. 2025 Aug 25;43(1):509. doi: 10.1007/s00345-025-05853-5.
6
Systems biology successes and areas for opportunity in prostate cancer.
Endocr Relat Cancer. 2025 Aug 20;32(8). doi: 10.1530/ERC-25-0067. Print 2025 Aug 1.
7
Anti-tumor activity of CDYL2b in prostate cancer.
Cancer Lett. 2025 Aug 12;632:217987. doi: 10.1016/j.canlet.2025.217987.
8
Proteomic profiling of extracellular vesicles distinguishes prostate cancer molecular subtypes.
bioRxiv. 2025 Aug 2:2025.07.31.667906. doi: 10.1101/2025.07.31.667906.
9
A Subset of HOX Genes Negatively Correlates with HOX/PBX Inhibitor Target Gene Expression and Is Associated with Apoptosis, DNA Repair, and Metabolism in Prostate Cancer.
Genes (Basel). 2025 Jul 15;16(7):824. doi: 10.3390/genes16070824.
10
Targeting USP42 induces DNA damage and inhibits cell growth in prostate cancer.
Front Mol Biosci. 2025 Jul 11;12:1646331. doi: 10.3389/fmolb.2025.1646331. eCollection 2025.
本文引用的文献
1
The landscape of somatic copy-number alteration across human cancers.
Nature. 2010 Feb 18;463(7283):899-905. doi: 10.1038/nature08822.
2
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.
Br J Cancer. 2010 Feb 16;102(4):678-84. doi: 10.1038/sj.bjc.6605554. Epub 2010 Jan 26.
3
A small-cell lung cancer genome with complex signatures of tobacco exposure.
Nature. 2010 Jan 14;463(7278):184-90. doi: 10.1038/nature08629. Epub 2009 Dec 16.
4
A comprehensive catalogue of somatic mutations from a human cancer genome.
Nature. 2010 Jan 14;463(7278):191-6. doi: 10.1038/nature08658. Epub 2009 Dec 16.
5
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
Cancer Cell. 2009 Dec 8;16(6):463-74. doi: 10.1016/j.ccr.2009.10.016.
6
Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate.
Cancer Cell. 2009 Oct 6;16(4):336-46. doi: 10.1016/j.ccr.2009.08.016.
7
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.
Cancer Cell. 2009 Aug 4;16(2):115-25. doi: 10.1016/j.ccr.2009.06.006.
8
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12465-70. doi: 10.1073/pnas.0905931106. Epub 2009 Jul 10.
9
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors.
Oncogene. 2009 Aug 6;28(31):2773-83. doi: 10.1038/onc.2009.135. Epub 2009 Jun 15.
10
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.
Mod Pathol. 2009 Aug;22(8):1083-93. doi: 10.1038/modpathol.2009.69. Epub 2009 May 1.
Zotero 插件